NEW YORK, Dec. 11, 2021 /PRNewswire-PRWeb/ — Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial. They shared their findings during an oral presentation at the American Society of Hematology annual meeting in December.
Patients on the therapy, called AVID200, showed improvements in symptom burden, anemia, and spleen enlargement. The results confirmed the therapy’s safety and showed some evidence of efficacy—though safety and finding the optimal dose was the primary goal—and researchers concluded that the therapy would need to be combined with other drugs to optimize impact in patients.
“This is a real testament to cutting-edge translational research at The Tisch Cancer Institute,” said John Mascarenhas, MD, Director of the Institute’s newly launched Center of Excellence for Blood Cancer and Myeloid Disorders, which was created to translate science into cures for patients with blood cancers. “Our scientists tested this therapy in the lab, physician-scientists conducted a successful phase 1 trial, and now the optimal combination therapy approach is the subject of ongoing laboratory studies at Mount Sinai. The most interesting finding in this trial was that a subset of patients had a lasting improvement in their platelet counts—including three whose counts were normalized—supporting the preclinical studies conducted by Mount Sinai researchers Ronald Hoffman, MD, Anna Rita Migliaccio, PhD, and Lillian Varricchio, PhD.”
Myelofibrosis is a type of bone marrow cancer that disrupts the normal production of blood cells, causing an enlarged spleen, extensive scarring in the bone marrow, and low levels of red blood cells and platelets, increasing the risk of bleeding. Myelofibrosis patients who have failed the available first-line therapy face a well-documented poor prognosis, so additional therapies are urgently needed to help these patients.
Twenty-one patients enrolled in this multicenter trial were given AVID200, and while this trial’s main purpose was to test safety, some patients had an increase in platelets and their enlarged spleens decreased in size. However, despite the clinical benefits observed, patients’ bone marrow scarring did not decline, so doctors believe that AVID200 likely needs to be combined with other rational therapies in the future.
In addition to this study, Mount Sinai has launched the new Center of Excellence for Blood Cancers and Myeloid Disorders to further deepen its commitment to quality care for blood and bone marrow cancer patients. A leader in the study and treatment of leukemias, including myeloproliferative neoplasms and myelodysplastic syndromes, the Center is one of the busiest and most well-recognized programs in the country. It is part of The Tisch Cancer Institute at Mount Sinai, a National Cancer Institute-designated Cancer Center.
The Center is focused on bringing multi-disciplinary, cutting-edge, highly personalized care to patients with all forms of blood cancer and myeloid disorders. The Center brings together world-leading physicians to provide exceptional patient care that draws from their experience, innovation, clinical trials, research, and education.
“At the Center of Excellence for Blood Cancers and Myeloid Disorders, we believe everyone deserves personalized and excellent care, so we develop an individualized treatment plan for you, using the latest technologies and advances in biologic understanding,” said Dr. Mascarenhas, who is also Professor of Medicine (Hematology and Medical Oncology) at Icahn Mount Sinai. “We use genetic, epigenetic, cell signaling, and immunologic factors in developing your treatment plan. We are skilled in stem cell transplantation, and we are experts at overcoming graft-versus-host-disease, one of the main challenges of stem cell transplant. Through this center, and our ongoing research, we will continue to make progress in the diagnosis and treatment of blood cancers among our patients.”
About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report’s “Honor Roll” of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children’s Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.
Marlene Naanes, Mount Sinai Health System, 212-241-9200, [email protected]
SOURCE Mount Sinai Health System